Advertisement

Advances in Therapy

, Volume 36, Issue 6, pp 1279–1290 | Cite as

Integrating Osimertinib in Clinical Practice for Non-Small Cell Lung Cancer Treatment

  • Senthil RajappaEmail author
  • M. Vamshi Krishna
  • Prasad Narayanan
Review
  • 148 Downloads

Abstract

Treatment of non-small cell lung cancer (NSCLC) is evolving with the use of precision medicine for patients with sensitizing epidermal growth factor receptor (EGFR) mutation. First- and second-generation EGFR tyrosine kinase inhibitors (TKIs) remained the standard of care for patients with EGFR-mutated advanced NSCLC for about a decade. However, treatment resistance eventually develops for most patients who experience initial response to these agents. The most commonly acquired resistance mechanism is the T790M gatekeeper mutation. Poor drug penetration leading to central nervous system (CNS) relapse and dose-limiting toxicities are other concerns. The third-generation EGFR-TKI osimertinib, initially approved as the second-line treatment for patients with T790-mutant NSCLC, demonstrated survival benefits in TKI-naïve EGFR-mutated patients, especially in patients with CNS metastasis. The FLAURA study has shown statistically significant progression-free survival benefit and prolongation of all post-progression outcome endpoints, time to first subsequent therapy, second subsequent therapy, and second progression on subsequent treatment, along with acceptable toxicity and better quality of life outcomes. These data favor osimertinib in the first-line setting for EGFR-mutated NSCLC. This is an important milestone since sequencing the TKI therapy based on accurate prediction of T790M is clinically challenging. In countries like India, T790M testing is not routinely conducted and two-thirds of patients with NSCLC do not receive any second-line therapy. Osimertinib can be administered pragmatically as a first-line therapy. Mature overall survival data from the FLAURA study will be important and could help define the optimal personalized treatment for patients with advanced NSCLC.

Funding: AstraZeneca Pharma India Ltd.

Keywords

Epidermal growth factor receptor tyrosine kinase inhibitors First-line Non-small cell lung cancer Osimertinib T790M 

Notes

Acknowledgements

Funding

The preparation of this article and funding of the journal’s article processing charges were supported by AstraZeneca Pharma India Ltd. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis.

Medical Writing Assistance

The authors thank Chinmayee Joshi from Sciformix Technologies Pvt. Ltd., Mumbai for providing medical writing assistance in the development of this manuscript. The authors also thank AstraZeneca Pharma India Ltd. for funding this assistance.

Authorship

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosures

Senthil Rajappa, M Vamshi Krishna, and Prasad Narayanan have nothing to disclose.

Compliance with Ethics Guidelines

This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Data Availability

Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

References

  1. 1.
    Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83:584–94.CrossRefGoogle Scholar
  2. 2.
    Sahoo R, Harini VV, Babu VC, et al. Screening for EGFR mutations in lung cancer, a report from India. Lung Cancer. 2011;73:316–9.CrossRefGoogle Scholar
  3. 3.
    Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–39.CrossRefGoogle Scholar
  4. 4.
    Stewart EL, Tan SZ, Liu G, Tsao MS. Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review. Transl Lung Cancer Res. 2015;4:67–81.Google Scholar
  5. 5.
    Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361:958–67.CrossRefGoogle Scholar
  6. 6.
    Santarpia M, Liguori A, Karachaliou N, et al. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy. Lung Cancer (Auckl). 2017;8:109–25.Google Scholar
  7. 7.
    Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123–32.CrossRefGoogle Scholar
  8. 8.
    Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–57.CrossRefGoogle Scholar
  9. 9.
    Douillard JY, Ostoros G, Cobo M, et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br J Cancer. 2014;110:55–62.CrossRefGoogle Scholar
  10. 10.
    Paz-Ares L, Tan EH, O’Byrne K, et al. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol. 2017;28:270–7.CrossRefGoogle Scholar
  11. 11.
    Nakamura A, Inoue A, Morita S, et al. Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009). J Clin Oncol. 2018;36:9005.CrossRefGoogle Scholar
  12. 12.
    Furuya N, Fukuhara T, Saito H, et al. Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations: NEJ026. J Clin Oncol. 2018;36:9006.CrossRefGoogle Scholar
  13. 13.
    Morgillo F, Della Corte CM, Fasano M, Ciardiello F. Mechanisms of resistance to EGFR-targeted drugs: lung cancer. ESMO Open. 2016;1:e000060.CrossRefGoogle Scholar
  14. 14.
    Mok TS, Cheng Y, Zhou X, et al. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. J Clin Oncol. 2018;36:2244–50.CrossRefGoogle Scholar
  15. 15.
    Patil VM, Noronha V, Joshi A, et al. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma. ESMO Open. 2017;2:e000168.CrossRefGoogle Scholar
  16. 16.
    Parikh P, Chang AY, Nag S, et al. Clinical experience with gefitinib in Indian patients. J Thorac Oncol. 2008;3:380–5.CrossRefGoogle Scholar
  17. 17.
    Noronha V, Prabhash K, Thavamani A, et al. EGFR mutations in Indian lung cancer patients: clinical correlation and outcome to EGFR targeted therapy. PLoS One. 2013;8:e61561.CrossRefGoogle Scholar
  18. 18.
    Louis RA, Rajendranath R, Ganesan P, Sagar TG, Krishnamurthy A. First report of upfront treatment with gefitinib in comparison with chemotherapy in advanced non-small cell lung cancer patients from south India: analysis of 120 patients. Indian J Med Paediatr Oncol. 2012;33:146–54.CrossRefGoogle Scholar
  19. 19.
    Cortot AB, Jänne PA. Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas. Eur Respir Rev. 2014;23:356–66.CrossRefGoogle Scholar
  20. 20.
    Schouten L, Rutten J, Huveneers H, Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer. 2002;94:2698–705.CrossRefGoogle Scholar
  21. 21.
    Chamberlain M, Kormanik P. Carcinoma meningitis secondary to non-small cell lung cancer: combined modality therapy. Arch Neurol. 1998;5:506–12.CrossRefGoogle Scholar
  22. 22.
    Liao B, Lee J, Lin C, et al. Epidermal growth factor receptor tyrosine kinase inhibitors for non-small-cell lung cancer patients with leptomeningeal carcinomatosis. J Thorac Oncol. 2015;10:1754–61.CrossRefGoogle Scholar
  23. 23.
    Omuro A, Kris M, Miller V, et al. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer. 2005;103:2344–8.CrossRefGoogle Scholar
  24. 24.
    Lee YJ, Choi HJ, Kim SK, et al. Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer. Cancer. 2010;116:1336–43.CrossRefGoogle Scholar
  25. 25.
    Jamal-Hanjani M, Spicer J. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain. Clin Cancer Res. 2012;18:938–44.CrossRefGoogle Scholar
  26. 26.
    Hoffknecht P, Tufman A, Wehler T, et al. Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease. J Thorac Oncol. 2015;10:156–63.CrossRefGoogle Scholar
  27. 27.
    Noronha V, Joshi A, Gokarn A, et al. The importance of brain metastasis in EGFR mutation positive NSCLC patients. Chemother Res Pract. 2014;2014:856156.Google Scholar
  28. 28.
    Biswas B, Ghadyalpatil N, Krishna MV, Deshmukh J. A review on adverse event profiles of epidermal growth factor receptor-tyrosine kinase inhibitors in nonsmall cell lung cancer patients. Indian J Cancer. 2017;54:S55–64.CrossRefGoogle Scholar
  29. 29.
    Yang JC, Ahn MJ, Kim DW, et al. Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component. J Clin Oncol. 2017;35:1288–96.CrossRefGoogle Scholar
  30. 30.
    Singh M, Jadhav HR. Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors. Drug Discov Today. 2018;23:745–53.CrossRefGoogle Scholar
  31. 31.
    Zhang H. Osimertinib making a breakthrough in lung cancer targeted therapy. Onco Targets Ther. 2016;6:5489–93.CrossRefGoogle Scholar
  32. 32.
    Cross DA, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4:1046–61.CrossRefGoogle Scholar
  33. 33.
    Yang J, Ramalingam SS, Janne PA, Cantarini M, Mitsudomi T. Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results. J Thorac Oncol. 2016;11:S152–3.CrossRefGoogle Scholar
  34. 34.
    Mok TS, Wu Y-L, Ahn M-J, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376:629–40.CrossRefGoogle Scholar
  35. 35.
    Janne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372:1689–99.CrossRefGoogle Scholar
  36. 36.
    Yang JC, Ahn MJ, Kim DW, et al. Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component. J Clin Oncol. 2017;35:1288–96.CrossRefGoogle Scholar
  37. 37.
    Goss G, Tsai CM, Shepherd FA, et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2016;17:1643–52.CrossRefGoogle Scholar
  38. 38.
    Mok T, Ju Ahn M, Youn Han J, Kang JH, Katakami N, Kim HR. CNS response to osimertinib in patients (pts) with T790M-positive advanced NSCLC: Data from a randomized phase III trial (AURA3). Accessed from: http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.9005#affiliationsContainer. 2018. Accessed 20 Sep 2018.
  39. 39.
    Ramalingam SS, Yang JC, Lee CK, et al. Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer. J Clin Oncol. 2018;36:841–9.CrossRefGoogle Scholar
  40. 40.
    Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113–25.Google Scholar
  41. 41.
    Yang JC, Cho BC, Kim DW, et al. Osimertinib for patients (pts) with leptomeningeal metastases (LM) from EGFR-mutant non-small cell lung cancer (NSCLC): updated results from the BLOOM study. http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.2020. 2018. Accessed 20 Sep 2018.
  42. 42.
    Lee CK, Novello S, Rydén A, Mann H, Mok T. Patient-reported symptoms and impact of treatment with osimertinib versus chemotherapy in advanced non-small-cell lung cancer: the AURA3 trial. J Clin Oncol. 2018;36:1853–60.CrossRefGoogle Scholar
  43. 43.
    Zanwar S, Noronha V, Joshi A, et al. Repeat biopsy in epidermal growth factor receptor mutation-positive nonsmall cell lung cancer: feasibility, limitations, and clinical utility in Indian patients. Indian J Cancer. 2017;54:280–4.CrossRefGoogle Scholar
  44. 44.
    Popat S. Osimertinib as first-line treatment in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2018;378:192–3.CrossRefGoogle Scholar
  45. 45.
    Leighl N, Karaseva N, Nakagawa K, et al. Patient-reported outcomes from FLAURA: osimertinib versus standard of care (SoC) epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC). J Thorac Oncol. 2018;13:S81–2.CrossRefGoogle Scholar
  46. 46.
    Cho BC, Chewaskulyong B, Lee KH, et al. Osimertinib vs standard of care (SoC) EGFR-TKI as first-line treatment in patients with EGFR-TKI sensitising mutation (EGFRm) positive advanced non-small cell lung cancer (NSCLC): FLAURA Asian subset. Ann Oncol. 2017;28(mdx729):008.Google Scholar
  47. 47.
    Wang F, Mishina S, Takai S, et al. Systemic treatment patterns with advanced or recurrent non-small cell lung cancer in Japan: a retrospective hospital administrative database study. Clin Ther. 2017;39:1146–60.CrossRefGoogle Scholar
  48. 48.
    Enewold L, Thomas A. Real-world patterns of EGFR testing and treatment with erlotinib for non-small cell lung cancer in the United States. PLoS One. 2016;11:e0156728.CrossRefGoogle Scholar
  49. 49.
    Wu YL, Sequist LV, Tan EH, et al. Afatinib as first-line treatment of older patients with EGFR mutation-positive non-small-cell lung cancer: subgroup analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 trials. Clin Lung Cancer. 2018;19:e465–79.CrossRefGoogle Scholar
  50. 50.
    Asahina H, Yamazaki K, Kinoshita I, et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer. 2006;95:998–1004.CrossRefGoogle Scholar
  51. 51.
    Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239–46.Google Scholar
  52. 52.
    Marinis FD, Cho C, Kim DW, et al. ASTRIS: a real world treatment study of osimertinib in patients (pts) with EGFR T790M positive non-small cell lung cancer (NSCLC). J Clin Oncol. 2017;35:9036.CrossRefGoogle Scholar
  53. 53.
    Hochmair M, Holzer S, Filipits M, et al. EGFR T790M resistance mutation in NSCLC: real-life data of Austrian patients treated with osimertinib. J Thorac Oncol. 2017;12:S1254.CrossRefGoogle Scholar
  54. 54.
    Devjak R, Hitij NT, Rajer M, Cufer T. CNS response to osimertinib in patients with EGFR mutated lung adenocarcinoma: real world data. J Thorac Oncol. 2018;13:S92–3.CrossRefGoogle Scholar
  55. 55.
    Noronha V, Pinninti R, Patil VM, Joshi A, Prabhash K. Lung cancer in the Indian subcontinent. South Asian J Cancer. 2016;5:95–103.CrossRefGoogle Scholar
  56. 56.
    Batra U, Lokeshwar N, Gupta S, Shirsath P. Role of epidermal growth factor receptor-tyrosine kinase inhibitors in the management of central nervous system metastases in epidermal growth factor receptor mutation-positive nonsmall cell lung cancer patients. Indian J Cancer. 2017;54:S37–44.CrossRefGoogle Scholar
  57. 57.
    Tang ZH, Lu JJ. Osimertinib resistance in non-small cell lung cancer: mechanisms and therapeutic strategies. Cancer Lett. 2018;420:242–6.CrossRefGoogle Scholar
  58. 58.
    Piotrowska Z, Thress KS, Mooradian M, et al. MET amplification (amp) as a resistance mechanism to osimertinib. J Clin Oncol. 2017;35:9020.CrossRefGoogle Scholar
  59. 59.
    Kim TM, Song A, Kim DW, et al. Mechanisms of acquired resistance to AZD9291: a mutation-selective, irreversible EGFR inhibitor. J Thorac Oncol. 2015;10:1736–44.CrossRefGoogle Scholar
  60. 60.
    Li L, Wang H, Li C, Wang Z, Zhang P, Yan X. Transformation to small-cell carcinoma as an acquired resistance mechanism to AZD9291: a case report. Oncotarget. 2017;8:18609–14.Google Scholar
  61. 61.
    Bersanelli M, Minari R, Bordi P, et al. L718Q mutation as new mechanism of acquired resistance to AZD9291 in EGFR-mutated NSCLC. J Thorac Oncol. 2016;11:e121–3.CrossRefGoogle Scholar
  62. 62.
    Planchard D, Loriot Y, Andre F, et al. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. Ann Oncol. 2015;26:2073–8.CrossRefGoogle Scholar
  63. 63.
    Ho CC, Liao WY, Lin CA, Shih JY, Yu CJ, Chih-Hsin Yang J. Acquired BRAF V600E mutation as resistant mechanism after treatment with osimertinib. J Thorac Oncol. 2017;12:567–72.CrossRefGoogle Scholar
  64. 64.
    Eberlein CA, Stetson D, Markovets AA, et al. Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models. Cancer Res. 2015;75:2489–500.CrossRefGoogle Scholar
  65. 65.
    Ortiz-Cuaran S, Scheffler M, Plenker D, et al. Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors. Clin Cancer Res. 2016;22:4837–47.CrossRefGoogle Scholar
  66. 66.
    Uchibori K, Inase N, Araki M, et al. Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat Commun. 2017;8:14768.CrossRefGoogle Scholar
  67. 67.
    Uchibori K, Inase N, Nishio M, Fujita N, Katayama R. Identification of mutation accumulation as resistance mechanism emerging in first-line osimertinib treatment. J Thorac Oncol. 2018;13:915–25.CrossRefGoogle Scholar
  68. 68.
    Yu HA, Hayes SA, Young RJ, Ni A, Rodriguez C, Makhnin A. A phase 1 study of osimertinib and bevacizumab as initial treatment for patients with EGFR-mutant lung cancers. J Clin Oncol. 2017;35:9033.Google Scholar
  69. 69.
    Yu H, Planchard D, Yang JC, et al. P1. 04-001 osimertinib with ramucirumab or necitumumab in advanced T790M-positive EGFR-Mutant NSCLC: preliminary Ph1 study results. J Thorac Oncol. 2017;12:S1972.Google Scholar

Copyright information

© Springer Healthcare Ltd., part of Springer Nature 2019

Authors and Affiliations

  • Senthil Rajappa
    • 1
    Email author
  • M. Vamshi Krishna
    • 2
  • Prasad Narayanan
    • 3
  1. 1.Medical Oncologist, Basavatarakam Indo-American Cancer Hospital and Research InstituteHyderabadIndia
  2. 2.Medical OncologyApollo HospitalsHyderabadIndia
  3. 3.Medical OncologyCytecare HospitalBengaluruIndia

Personalised recommendations